Business Context and Reporting Period
This Form 6-K filing by James Hardie Industries N.V. (now James Hardie Industries Plc) was submitted to the SEC on September 27, 2004. The registrant is a foreign private issuer headquartered in Amsterdam, The Netherlands. The filing serves to disclose specific corporate actions and regulatory communications filed with the Australian Stock Exchange (ASX) on September 21, 2004.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing external exhibits and does not contain a financial results summary or balance sheet data.
Material Changes
No material financial changes versus a prior comparable period are detailed in this text. The filing focuses on the submission of a request to lift a trading halt and the release of a report from a Special Commission of Inquiry regarding the Mesothelioma Research and Compensation Scheme (MRCS).
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes a Safe Harbor Statement cautioning that forward-looking statements involve inherent risks. Factors that could cause actual results to differ materially include competition, pricing, economic conditions, environmental laws, cyclical construction markets, raw material costs, distributor reliance, product failures, and legal proceedings.
Contingencies and Unusual Items: The primary subject of this filing is the Special Commission of Inquiry into the MRCS. The company filed a request to lift a trading halt on its shares alongside the inquiry report, indicating significant regulatory and reputational contingencies related to this matter.
Investor Verification Checklist
- Verify the full text of the Special Commission of Inquiry report into the MRCS (Exhibit 99.1).
- Confirm the status of the trading halt on the Australian Stock Exchange following the September 21, 2004 request.
- Review the company's specific statement regarding the inquiry report (Exhibit 99.2).
- Assess potential legal and financial liabilities arising from the MRCS findings.
- Check subsequent filings for any updates on the trading status or regulatory outcomes.